Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction

I. Hubloue*, D. Biarent*, S. Abdel Kafi*, G. Bejjani*, F. Kerbaul*, R. Naeije*, M. Leeman*

Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction. I. Hubloue, D. Biarent, S. Abdel Kafi, G. Bejjani, F. Kerbaul, R. Naeije, M. Leeman. ©ERS Journals Ltd 2003.

ABSTRACT: The effects of endothelin receptor blockade on the pulmonary circulation have been reported variably, possibly in relation to a more or less important associated release of endogenous nitric oxide (NO). The aim of this study was to test whether endothelin antagonism would inhibit hypoxic pulmonary vasoconstriction, and if it would not, then would it do so after NO synthase inhibition.

Hypoxic pulmonary vasoconstriction (HPV) was evaluated in anesthetised dogs by the increase in the mean pulmonary artery pressure (P_{Pa}) minus occluded P_{Pa} (P_{PaO}) gradient in response to hypoxia (inspiratory oxygen fraction of 0.1) at constant pulmonary blood flow.

Bosentan, an endothelin A and B receptor antagonist, did not affect baseline P_{Pa}, P_{PaO} or systemic arterial pressure (P_{a}) and did not alter HPV (n=8). The NO synthase inhibitor N^{G}-nitro-L-arginine (L-NA) did not affect baseline P_{Pa} and P_{PaO}, but increased P_{Pa} and enhanced HPV (n=12). The addition of bosentan in these dogs did not affect baseline P_{Pa} or P_{PaO}, but decreased P_{Pa} and inhibited HPV. Exhaled NO was decreased by L-NA and by bosentan and abolished by L-NA+bosentan (n=9).

The authors conclude that endogenous nitric oxide is released by, and opposes the vasoconstricting effects of, endothelins in vivo, reducing systemic blood pressure and limiting hypoxic pulmonary vasoconstriction.

Eur Respir J 2003; 21: 19–24.

Endothelins are potent endothelium-derived vasoconstrictors [1]. The endothelin system has been reported to be activated in various types of experimental or clinical pulmonary hypertension [1]. However, whether endogenous endothelins play a role in the control of systemic and pulmonary vascular tone in vivo remains uncertain. Endothelin receptor antagonists have been shown to increase forearm blood flow in humans [2, 3], to reduce brachial artery pressure in patients with essential hypertension [4] and to decrease pulmonary artery pressure in patients with primary pulmonary hypertension [5, 6]. However, some investigators have been unable to demonstrate pulmonary or systemic vascular effects of these compounds in vivo [7–17]. The failure to show a vasoconstrictor effect of endogenous endothelins appears related, at least in part, to the release of nitric oxide (NO) by the endothelium, which either counteracts the effect and/or inhibits the synthesis of endothelins [16–19].

Endothelins have been hypothesised to play a role in the mediation of hypoxic pulmonary vasoconstriction (HPV). Hypoxia has been reported to increase the level of immunoreactive endothelin-1 in the plasma and of endothelin-1 messenger ribonucleic acid in the lung and right atrium [12, 20]. However, selective as well as nonselective endothelin receptor blockers have been shown to inhibit HPV in some studies [8–14] but not in others [15, 21–23]. These discrepancies might be explained, at least in part, by variable release of endogenous NO, which has been shown to limit HPV in intact animals [24, 25].

In this study, the effects of endogenous endothelins on hyperoxic and hypoxic vascular tone, with and without NO synthase inhibition by N^{G}-nitro-L-arginine (L-NA), were examined. The hypothesis was that endothelin antagonism may inhibit HPV, but if not, would do so after NO synthase inhibition. Because endothelins have opposite vascular effects, possibly mediated by different receptors [1], complete blockade of the actions of endogenous endothelins requires antagonism of both endothelin A and endothelin B receptors, as exerted by the combined nonpeptide blocker bosentan [26]. The effects of hypoxia and drugs on vascular tone were evaluated at constant cardiac output (Q') to allow for the discrimination between passive and active tone dependent changes in pulmonary vascular pressure [24, 25].

Methods

The experiments were conducted in agreement with the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health and were approved by the Committee on the Care and Use
of Animals in Research of the Brussels Free University School of Medicine, Brussels, Belgium.

**Animal preparation**

Mongrel dogs (16–45 kg) were anaesthetised (pentobarbitral 25 mg kg⁻¹ intravenously followed by 2 mg kg⁻¹ hourly), paralysed (pancuronium 0.2 mg kg⁻¹ intravenously followed by 0.2 mg kg⁻¹ hourly), intubated and ventilated (Elema 900 B Servo ventilator; Siemens, Solna, Sweden) with an inspiratory oxygen fraction (F₁O₂) of 0.4. This higher than normal F₁O₂ was selected to maintain the lungs above the threshold for HPV [25]. Catheters were placed in the jugular vein, in the femoral artery and in the pulmonary artery as described previously [24, 25]. Cardiac output was measured by thermodilution. A balloon catheter was advanced into the inferior vena cava through a right femoral venotomy and a large-bore cannula was inserted into the left femoral artery and vein to act as an arteriovenous bypass. Stepwise inflations of the balloon catheter or opening of the bypass decreased or increased Q', respectively [24, 25].

**Effect of big endothelin-1 without and with bosentan**

Bosentan (Actelion, Allschwil, Switzerland) was diluted in heated distilled water just before the experiments and administered as an intravenous bolus of 3 mg kg⁻¹ followed by a constant infusion of 7 mg kg⁻¹ h⁻¹ [7]. This dose has been shown to provide optimal endothelin receptor blockade in dogs [7]. The ability of this dose of bosentan to antagonise the effects of big endothelin-1 (Novabiochem, Laufelfingen, Switzerland), the precursor of endothelins, was checked. Big endothelin-1 was diluted in sodium chloride 0.9% just before the experiments. After two baseline hypoxic challenges (F₁O₂ 0.4–0.1 for 6 min), the dogs received 1 nmol kg⁻¹ of big endothelin-1 alone (n=3) or after bosentan (n=2), and two additional hypoxic challenges were performed thereafter. Q' was kept constant using the femoral bypass and the inferior vena cava balloon. Mean pulmonary artery pressure (Pₚₚₚ), occluded Pₚₚ (Pₚₚₚₚ), systemic artery pressure (Pₚₚₚ), Q' and blood gases were measured after 3 min stabilisation.

**Effect of bosentan**

The response of the Pₚₚₚₚ–Pₚₚₒ gradient to changes in F₁O₂ (0.4, 0.21, 0.12, 0.1) was examined, with Q' kept constant, before and after bosentan. Each F₁O₂ was maintained for at least 6 min to allow stabilisation.

**Effect of bosentan after NG-nitro-L-arginine**

Two hypoxic challenges (F₁O₂ 0.4–0.1) were performed at baseline, after l-NA (Sigma-Aldrich, Bornem, Belgium) 5 mg kg⁻¹ intravenous bolus followed by a constant infusion of 5 mg kg⁻¹ h⁻¹, and again after bosentan. This dose of l-NA has been shown to enhance canine HPV [24, 25]. Q' was kept constant as described above.

**Effect of NG-nitro-L-arginine and bosentan on exhaled nitric oxide**

The concentration of NO was continuously monitored at the tip of the endotracheal tube using a chemiluminescence analyser (Model LR2000; Logan Research, Rochester, UK) [27]. Exhaled NO concentrations were read in triplicate at the maximum value of expired carbon dioxide. These measurements were performed after bosentan alone (n=4), after l-NA (n=5) and after bosentan given after l-NA (n=4).

**Analysis of the data**

Results are expressed as means±SEM. A two-factor analysis of variance for multiple measurements and modified t-tests were used as appropriate [24, 25, 28]. Values of p<0.05 were considered as significant.

**Results**

**Effects of big endothelin-1 without and with bosentan**

As designed in the protocol, Q' was kept constant in all experiments.

**Big endothelin-1 alone.** At F₁O₂ 0.4, big endothelin-1 increased Pₚₚₚₚ from 104 to 132 mmHg and had no effect on Pₚₚₚₚ–Pₚₚₒ which was 8 mmHg before and after big endothelin-1. The increase in Pₚₚₚₚ–Pₚₚₒ in response to hypoxia was 2 mmHg before and 4 mmHg after big endothelin-1 (n=3).

**Bosentan followed by big endothelin-1.** At F₁O₂ 0.4, bosentan slightly reduced Pₚₚₚₚ from 118 to 109 mmHg. Big endothelin-1 given after bosentan had no effect on Pₚₚₚₚ, which remained at 105 mmHg. Pₚₚₚₚ–Pₚₚₒ remained at 8 mmHg at baseline, 8 mmHg after bosentan and 8 mmHg after big endothelin-1. Hypoxia-induced increases in Pₚₚₚₚ–Pₚₚₒ were 11 mmHg at baseline, 11 mmHg after bosentan and 10 mmHg after big endothelin-1 (n=2).

**Effects of bosentan alone**

Hypoxia increased the Pₚₚₚₚ–Pₚₚₒ gradient measured at constant Q' (table 1 and fig. 1). Administration of bosentan did not affect Pₚₚₚₚ–Pₚₚₒ in hyperoxia, normoxia and hypoxia (fig. 1). Neither hypoxia nor bosentan significantly affected Pₚₚₚₚ (table 1) (n=8).

**Effects of bosentan after NG-nitro-L-arginine**

At constant Q', bosentan inhibited the l-NA-induced increase in HPV (fig. 2) (n=12). Bosentan
Table 1. - Effects of bosentan at different inspiratory oxygen fractions \( (F_{I,O_2}) \) in eight dogs

| \( F_{I,O_2} \) | 0.4 | 0.21 | 0.12 | 0.1 | p-value |
|------------------|-----|------|------|-----|---------|
| \( Q^' \) L\text{-}min^{-1} \text{m}^{-2} |     |      |      |     |         |
| Baseline         | 4.9±0.5 | 4.8±0.5 | 4.8±0.5 | 4.8±0.5 | NS |
| Bosentan         | 5.0±0.5 | 4.8±0.5 | 4.8±0.5 | 4.8±0.5 | NS |
| \( P_{pa} \) mmHg |     |      |      |     |         |
| Baseline         | 12±1 | 11±1 | 13±1 | 16±1 | <0.01 |
| Bosentan         | 11±1 | 11±1 | 13±1 | 15±1 | <0.01 |
| \( P_{pao} \) mmHg |     |      |      |     |         |
| Baseline         | 3±1 | 2±1 | 2±1 | 2±1 | NS |
| Bosentan         | 2±1 | 2±1 | 1±1 | 2±1 | NS |
| \( P_{pao} \) mmHg |     |      |      |     |         |
| Baseline         | 109±10 | 114±12 | 123±15 | 122±17 | NS |
| Bosentan         | 105±9 | 104±14 | 108±14 | 104±11 | NS |
| \( f_c \) beats\text{-}min^{-1} |     |      |      |     |         |
| Baseline         | 152±4 | 152±7 | 160±8 | 157±8 | NS |
| Bosentan         | 154±7 | 155±9 | 166±7 | 162±6 | NS |
| \( pHa \) |     |      |      |     |         |
| Baseline         | 7.32±0.03 | 7.33±0.01 | 7.35±0.01 | 7.34±0.02 | NS |
| Bosentan         | 7.34±0.01 | 7.34±0.02 | 7.36±0.02 | 7.37±0.02 | NS |
| \( P_{a,O_2} \) mmHg |     |      |      |     |         |
| Baseline         | 204±11 | 99±5 | 46±2 | 35±2 | <0.01 |
| Bosentan         | 213±16 | 98±8 | 47±4 | 35±3 | <0.01 |
| \( P_{a,CO_2} \) mmHg |     |      |      |     |         |
| Baseline         | 45±2 | 41±2 | 41±2 | 40±3 | NS |
| Bosentan         | 39±3 | 37±2 | 37±3 | 38±3 | NS |
| \( P_{r,O_2} \) mmHg |     |      |      |     |         |
| Baseline         | 62±4 | 51±3 | 32±2 | 26±2 | <0.01 |
| Bosentan         | 59±4 | 52±4 | 34±4 | 27±3 | <0.01 |

Data are presented as mean±SEM. p-value: level of significance of the F-ratio of the analysis of variance; \( Q' \): cardiac index; \( P_{pa} \): mean pulmonary artery pressure; \( P_{pao} \): pulmonary artery occluded pressure; \( P_{aac} \): mean systemic artery pressure; \( f_c \): cardiac frequency; \( pHa \): arterial pH; \( P_{a,O_2} \): oxygen tension in arterial blood; \( P_{a,CO_2} \): carbon dioxide tension in arterial blood; \( P_{r,O_2} \): oxygen tension in mixed venous blood.

Effects on exhaled nitric oxide

Exhaled NO was 0.96±0.12 parts per billion (ppb) in hyperoxia and 1.01±0.13 ppb in hypoxia (p=NS, n=9). L-NA decreased exhaled NO to 0.42±0.16 ppb in hyperoxia and 0.39±0.17 in hypoxia (p<0.01 compared to baseline at the same \( F_{I,O_2} \); p=NS hypoxia compared to hypoxia, n=5). Bosentan alone decreased exhaled NO to 0.17±0.05 ppb in hyperoxia and 0.14±0.07 ppb in hypoxia (p<0.01 compared to baseline at the same \( F_{I,O_2} \), n=4). L-NA followed by bosentan decreased exhaled NO to 0.05±0.03 ppb in hyperoxia and in hypoxia (p<0.01 compared to baseline, n=4).

Discussion

The present results show that endothelin receptor antagonism by bosentan has no effects on pulmonary or systemic haemodynamics in normoxic nor in hypoxic conditions, but that it inhibits the enhancement of acute HPV and the increase in systemic blood pressure observed after NO synthase inhibition. As bosentan decreased exhaled NO, it appears that endothelins inhibit their own vasoconstricting effect by generating NO. Since a combined endothelin A and B receptor antagonist were used, the results also reduced the systemic arterial hypertension induced by l-NA in hyperoxia and in hypoxia (table 2).
cannot identify the respective effects of these receptors on HPV and exhaled NO.

**Pulmonary and systemic vascular tone during hyperoxia and normoxia**

The present results are in agreement with a previous observation that combined endothelin A and B receptor blockade by bosentan does not affect pulmonary nor systemic haemodynamics in well-oxygenated dogs [7], and may suggest that endogenous endothelins do not contribute to basal vascular control. However, an alternative explanation could be that a tonic release of endothelins occurs without demonstrable vasodilatation because of antagonistic release of NO or other endogenous vasodilator mediators [16–19]. The current data suggest that this is the case for the systemic but not the pulmonary circulation, since inhibition of NO synthesis did not affect pulmonary vascular resistance but was associated with a bosentan-reversible increase in systemic vascular resistance [17].

**Hypoxic pulmonary vasoconstriction**

In the present study, HPV was not affected by bosentan, given at a dose verified to block the vascular effects of the endothelin precursor big endothelin-1. It is of interest that big endothelin-1 alone markedly increased systemic vascular resistance but had no effect on hyperoxic or hypoxic pulmonary vascular resistance. Other authors have also been unable to inhibit HPV with endothelin receptor antagonists, including bosentan [15, 21–23]. Variable results of effects of endothelin receptor blockers on HPV in different experimental models may be explained by variable antagonism of tonic effects of endothelins by circulating or endothelium-derived vasodilating mediators.

**Bosentan after nitric oxide inhibition**

The current authors previously reported that inhibition of NO synthase enhances HPV in intact anesthetised dogs [24, 25]. Therefore, the effects of endothelin receptor blockade by bosentan after inhibition of NO synthase were tested. The present results confirm that NO synthase inhibition does not affect pulmonary vascular tone in well oxygenated dogs, but that it increases HPV [24, 25]. They additionally show that NO synthase inhibition unmasks a pulmonary vasoconstrictor effect of endothelins but only in acute hypoxia. This result is in agreement with a previous observation that combined endothelin A and B receptor antagonism inhibits the pulmonary vasoconstrictor response to L-NA in isolated perfused lungs from rats with chronic hypoxic pulmonary hypertension [19]. The hypertensive foetal pulmonary circulation also dilates in response to the administration of endothelin receptor antagonists [29, 30]. These studies indicate that pulmonary hypertension may not be fully explained by differences in NO synthase activity, but may involve other mediators.

### Table 2. – Effects of bosentan after N<sup>3</sup>-nitro-L-arginine (L-NA) in 12 dogs

|                  | Baseline      | F<sub>1.O2</sub> 0.4 | F<sub>1.O2</sub> 0.1 | L-NA           | F<sub>1.O2</sub> 0.4 | F<sub>1.O2</sub> 0.1 | L-NA+bosentan | F<sub>1.O2</sub> 0.4 | F<sub>1.O2</sub> 0.1 |
|------------------|---------------|----------------------|----------------------|-------------------|----------------------|----------------------|-------------------|----------------------|----------------------|
| Q’ L·min<sup>−1</sup>·m<sup>−2</sup> | 3.3±0.3       | 3.4±0.3              | 3.2±0.3              | 3.1±0.3           | 3.3±0.3              |
| P<sub>p</sub> mmHg | 12±1          | 18±2*                | 19±2*                | 18±2*             | 22±3*                |
| P<sub>pao</sub> mmHg | 4±1          | 3±1                  | 10±2*                | 8±1*              | 5±1                  |
| P<sub>a</sub> mmHg | 113±7         | 109±7                | 145±8*               | 125±7*            | 130±8*               |
| f<sub>c</sub> beats·min<sup>−1</sup> | 149±8         | 157±8                | 115±6*               | 121±7*            | 145±8               |
| pH<sub>a</sub>    | 7.33±0.01     | 7.35±0.01            | 7.36±0.01            | 7.37±0.01         | 7.37±0.01            | 7.39±0.02            |
| P<sub>a</sub> CO<sub>2</sub> mmHg | 195±12       | 36±1*                | 201±7                | 160±14*           | 32±2*                |
| P<sub>a</sub> O<sub>2</sub> mmHg | 37±1         | 33±1*                | 35±1*                | 34±1              | 33±2                |
| P<sub>v</sub> O<sub>2</sub> mmHg | 51±2         | 24±2*                | 46±1                 | 43±3              | 22±1*                |

Data are presented as mean±SEM. F<sub>1.O2</sub>: inspiratory oxygen fraction; Q’: cardiac index; P<sub>p</sub>: mean pulmonary artery pressure; P<sub>pao</sub>: pulmonary artery occluded pressure; P<sub>a</sub>: mean systemic artery pressure; f<sub>c</sub>: cardiac frequency; pH<sub>a</sub>: arterial pH; P<sub>a</sub> O<sub>2</sub>: oxygen tension in arterial blood; P<sub>a</sub> CO<sub>2</sub>: carbon dioxide tension in arterial blood; P<sub>v</sub> O<sub>2</sub>: oxygen tension in mixed venous blood. *: p<0.05 compared with F<sub>1.O2</sub> 0.4, same drug condition; **: p<0.05 compared with L-NA, same F<sub>1.O2</sub>; ***: p<0.05 compared with baseline, same F<sub>1.O2</sub>.
result from an imbalance of endothelin-1 receptor activation favouring pulmonary vasoconstriction [29], or from a combination of enhanced endothelin A receptor-mediated vasoconstriction together with a decreased NO synthase activity [30].

In the present study, bosentan reduced 1-NA-induced systemic hypertension. In anesthetised rats, mixed endothelin A and endothelin B receptor antagonism and selective endothelin A receptor antagonism did not affect $P_{aw}$ when given alone, but decreased it after NO synthase inhibition [16, 17]. Blockade of NO synthase also increased the plasma levels of endothelin-1 [17]. Compared to normotensive controls, hypertensive patients had larger vasodilatation in response to endothelin antagonism and smaller vasoconstriction in response to NO synthase inhibition, both responses being inversely correlated [2]. In accordance with these results, the present data suggest that the systemic hypertensive effect of NO synthase inhibition could be endothelin-mediated.

**Exhaled nitric oxide**

As expected, a decrease in exhaled NO was observed after NO synthase inhibition. The current results additionally show, for the first time, that bosentan also reduces exhaled NO. This observation suggests that the vasoconstrictive effects of endothelins are self-limited by an endothelin-induced synthesis of endogenous NO. Although it is generally proposed that endothelial NO synthesis is related to endothelin B receptor stimulation [1, 31, 32], a recent study shows that activation of endothelin A receptors also can enhance NO production in the vasculature [33]. Patients with acute respiratory distress syndrome have arterial hypoxaemia partially due to inefficient HPV, possibly related to the release of NO [34]. The current results show that bosentan does not inhibit HPV and decreases NO release. It could be speculated that bosentan might be given to reduce pulmonary hypertension in patients with ventilation-to-perfusion impairment, without further deteriorating gas exchange, as usually observed after systemic administration of vasodilators. This hypothesis could be tested in experimental models of lung injury.

**Clinical relevance and conclusions**

The current authors propose that endothelins stimulate nitric oxide production in pulmonary vessels, which counteracts their own constricting effect, and that the vasoconstricting action of endothelins can appear only when endogenous nitric oxide synthesis is deficient. The present results are in keeping with the concept that increased pulmonary vascular tone may result from an imbalance between the antagonistic effects of nitric oxide and endothelins, and that pharmacological manipulation of this imbalance offers therapeutic possibilities in pulmonary hypertension. The lungs of patients with severe pulmonary hypertension show a reduced expression of endothelial nitric oxide synthase [35] and an increased expression of endothelin-1 [36]. Endothelin receptor antagonism with bosentan has been reported recently to decrease pulmonary vascular resistance and to improve functional class and exercise capacity in patients with primary pulmonary hypertension [5, 6].

**Acknowledgements.** The authors would like to thank M. Clozel (Actelion, Allschwil, Switzerland) for the generous gift of bosentan. The expert technical assistance of P. Jespers, M-T. Gautier, A. Van Muylem and V. Martinet was greatly appreciated.

**References**

1. Michael JR, Markewitz BA. Endothelins and the lung. *Am J Respir Crit Care Med* 1996; 154: 555–581.
2. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. *Circulation* 1999; 100: 1680–1683.
3. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin B receptor blockade. *Circulation* 1998; 97: 752–756.
4. Krum H, Viskoper RJ, Lacouriere Y, Budde M, Charlon V, for the Bosentan Hypertension Investigators. The effects of endothelin-receptor antagonist, bosentan, on blood pressure in patients with arterial hypertension. *N Engl J Med* 1998; 338: 784–790.
5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 2002; 346: 896–903.
6. Channick RN, Simmoneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet* 2001; 358: 1119–1123.
7. Teerlink JR, Carteaux JP, Sprecher U, Löffler BM, Clozel M, Clozel JP. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. *Am J Physiol* 1995; 268: H432–H440.
8. Sato K, Morio Y, Morris KG, Rodman DM, McMurtry IF. Mechanism of hypoxic pulmonary vasoconstriction involves endothelin A receptor-mediated inhibition of KATP channel. *Am J Physiol* 2000; 278: L434–L442.
9. Holm P, Liska J, Franco-Cereceda A. The endothelin A receptor antagonist, BMS-182874, reduces acute hypoxic pulmonary hypertension in pigs in vivo. *Cardiovasc Res* 1998; 37: 765–771.
10. Willette RN, Oihlstein EH, Mitchell MP, et al. Nonpeptide endothelin receptor antagonists. VII: attenuation of acute hypoxia-induced pulmonary hypertension in the dog. *J Pharmacol Exp Ther* 1997; 280: 695–701.
11. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. *J Appl Physiol* 1995; 79: 2122–2131.
12. Oparil S, Chen SJ, Meng QC, Ellson TS, Yano M, Chen YF. Endothelin-A receptor antagonist prevents
acute hypoxia-induced pulmonary hypertension in the rat. Am J Physiol 1995; 268: L95–L100.

13. Wang Y, Coe Y, Toyoda O, Coceani F. Involvement of endothelin-1 in hypoxic pulmonary vasoconstriction in the lamb. J Physiol 1995; 482: 421–434.

14. Bonvallet ST, Zamora MR, Hasunuma K, et al. BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1994; 266: H1327–H1331.

15. Wong J, Vanderford PA, Winters JW, Chang R, Soifer SJ, Fineman JR. Endothelin-1 does not mediate acute hypoxic pulmonary vasoconstriction in the intact newborn lamb. J Cardiovasc Pharmacol 1993; 22: S262–S266.

16. Banting JD, Friberg P, Adams MA. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J Hypertens 1996; 14: 975–981.

17. Richard V, Hogie M, Clozel M, Löffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995; 91: 771–775.

18. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92: 99–104.

19. Muramatsu M, Rodman DM, Oka M, McMurtry IF. Endothelin-1 mediates nitro-L-arginine vasoconstriction of hypertensive rat lungs. Am J Physiol 1997; 272: L807–L812.

20. Elton TS, Oparil S, Taylor GR, et al. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992; 263: R1260–R1264.

21. Leeman M, Zegers de Beyl V, Gilbert E, Mélot C. Is nitric oxide released in oleic acid lung injury? Am J Physiol 1999; 276: L571–L581.

22. Fujii Y, Magder S, Cernacek P, Goldberg P, Guo Y, Hussain SNA. Endothelin receptor blockade attenuates lipopolysaccharide-induced pulmonary nitric oxide production. Am J Respir Crit Care Med 2000; 161: 982–989.

23. Douglas SA, Vickery-Clark LM, Ohlstein EH. Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ-123. Br J Pharmacol 1993; 108: 418–421.

24. Leeman M, Zegers de Beyl V, Biarent D, Maggiorini M, Mélot C, Naeije R. Inhibition of cyclooxygenase and nitric oxide synthase in hypoxic vasoconstriction and oleic acid-induced lung injury. Am J Respir Crit Care Med 1999; 159: 1383–1390.